肿瘤细胞治疗研究
英文原题：CAR T Cell Toxicities and Emerging Treatment Strategies.
嵌合抗原受体（CAR）T 细胞疗法已经彻底改变了复发或难治性 B 细胞恶性肿瘤和多发性骨髓瘤的结局，目前即将对实体瘤患者产生重大影响。
嵌合抗原受体（CAR）T细胞疗法已彻底改变复发或难治性B细胞恶性肿瘤和多发性骨髓瘤的治疗结局，目前也即将对实体瘤患者产生重大影响。然而，抗肿瘤应答常伴随免疫过度激活导致的急性毒性，包括细胞因子释放综合征、免疫效应细胞相关神经毒性综合征、免疫效应细胞相关血液毒性，以及免疫效应细胞相关噬血细胞性淋巴组织细胞增多症样综合征。本文讨论这些毒性的临床表现、评估、管理、危险因素和病理生理机制，并简要介绍正在发展的毒性缓解策略。
Having already revolutionized outcomes for relapsed or refractory B cell malignancies and multiple myeloma, chimeric antigen receptor (CAR) T cell therapy is on the cusp of significantly impacting those with solid tumors. However, antitumor response is frequently associated with acute toxicities due to immune hyperactivation, including cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, immune effector cell-associated hematotoxicity, and immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome. We discuss the clinical presentations, evaluation, management, risk factors, and pathophysiologies of these toxicities and briefly describe emerging toxicity mitigation strategies.
MEMBER ACCOUNT
登录成功会直接打开下一页。
